Antisense hypoxia-inducible factor-1α augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats

Human Gene Therapy

Volumn 20, Issue 4, 2009, Pages 314-324

  Sun, Xueying ^a,b   Jiang, Hongchi ^a   Jiang, Xian ^a   Tan, Hongtao ^a   Meng, Qinghui ^a   Sun, Bei ^a   Xu, Ruian ^c   Krissansen, Geoffrey W ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c HUAQIAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; ARTIFICIAL EMBOLISM; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; GENE; GENE EXPRESSION; HIF 1 GENE; INTRAPORTAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER ISCHEMIA; LIVER NECROSIS; LIVER TUMOR; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; TUMOR CELL; VEGF GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CELL DEATH; CELL PROLIFERATION; DEPENDOVIRUS; DOWN-REGULATION; DRUG ADMINISTRATION ROUTES; DRUG SYNERGISM; EMBOLIZATION, THERAPEUTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; RNA, ANTISENSE; TRANSGENES;

RATTUS;

EID: 64049098319     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.164     Document Type: Article

References (56)

1. Breedis, C., and Young, G. (1954). The blood supply of neoplasms in the liver. Am. J. Pathol. 30, 969-985.
2. Bruix, J., Llovet, J.M., Castells, A., Montana, X., Bru, C., Ayuso, M.C., Vilana, R., and Rode's, J. (1998). Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma, results of a randomized, controlled trial in a single institution. Hepatology 27, 1578-1583.
3. Dang, D.T., Fang, C., Gardner, L.B., Cummins, J.M., Rago, C., Bunz, F., Kantsevoy. S.V., and Dang, L.H. (2006). Hypoxiainducible factor-1α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res. 66, 1684-1693.
4. de Roos, W.K., Fallaux, F.J., Marinelli, A.W., Lazaris-Karatzas, A., von Geusau, A.B., van der Eb, M.M. Cramer, S.J., Terpstra, O.T., and Hoeben, R.C. (1997). Isolated-organ perfusion for local gene delivery, efficient adenovirus-mediated gene transfer into the liver. Gene Ther. 4, 55-62.
5. Dixelius, J, Larsson, H, Sasaki, T, Holmqvist, K, Lu, L, Engstrom, A., Timpl, R., Welsh, M., and Claesson-Welsh, L. (2000). Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95, 3403-3411.
6. Fedele, A.O., Whitelaw, M.L., and Peet, D.J. (2002). Regulation of gene expression by the hypoxia-inducible factors. Mol. Interv. 2, 229-243.
7. Fulda, S., and Debatin, K.M. (2007). HIF-1-regulated glucose metabolism, a key to apoptosis resistance? Cell Cycle 6, 790-792.
8. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U., and Stein, H. (1984). Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710-1715.
9. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. (1995). A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 332, 1256-1261.
10. Guo, W.J., Li, J., Chen, Z., Zhuang, J.Y., Gu, W.H., Zhang, L., Pang, J., Lu, C.H., Zhang, W.Z., and Cheng, Y.F. (2004). Transient increased expression of VEGF and MMP-1 in a ratliver tumor model after hepatic arterial occlusion. Hepatogastroenterology 51, 381-386.
11. Han, H.K., Han, C.Y., Cheon, E.P., Lee, J., and Kang, K.W. (2007). Role of hypoxia-inducible factor-α in hepatitis-B-virus X protein-mediated MDR1 activation. Biochem. Biophys. Res. Commun. 357, 567-573.
12. Hanazaki, K., Kajikawa, S., Shimozawa, N., Mihara, M., Shimada, K., Hiraguri, M., Koide, N., Adachi, W., and Amano, J. (2000). Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J. Am. Coll. Surg. 191, 381-388.
13. Harris, A.L. (2002). Hypoxia: a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 38-47.
14. Hockel, M., and Vaupel, P. (2001). Tumor hypoxia, definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276.
15. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 95, 7987-7992.
16. Jiang, H., Meng, Q., Tan, H., Pan, S., Sun, B., Xu, R., and Sun, X. (2007). Anti-angiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int. J. Cancer 121, 416-424.
17. Kallio, P.J., Wilson, W.J., O'Brien, S., Makino, Y., and Poellinger, L. (1999). Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274, 6519-6525.
18. Kim, Y.B., Park, Y.N., and Park, C. (2001). Increased proliferation activities of vascular endothelial cells and tumor cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38, 160-166.
19. Ko, Y.H., Pedersen, P.L., and Geschwind, J.F. (2001). Glucose catabolism in the rabbit VX2 tumor model for liver cancer, characterization and targeting hexokinase. Cancer Lett. 173, 83-91.
20. Kunz, M., and Ibrahim, S.M. (2003). Molecular responses to hypoxia in tumor cells. Mol. Cancer 2, 23.
21. Lai, E.C., Lo, C.M., Fan, S.T., Liu, C.L., and Wong, J. (1998). Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma, a randomized controlled trial. Arch. Surg. 133, 183-188.
22. Li, X., Feng, G.S., Zheng, C.S., Zhou, C.K., and Liu, X. (2004). Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878-2882.
23. Liao, X.F., Yi, J.L., Li, X.R., Deng, W., Yang, Z.F., and Tian, G. (2004). Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J. Gastroenterol. 10, 1885-1889.
24. Lien, W.M., and Ackerman, N.B. (1970). The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68, 334-340.
25. Liou, T.C., Shih, S.C., Kao, C.R., Chou, S.Y., Lin, S.C., and Wang, H.Y. (1995). Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J. Hepatol. 23, 563-568.
26. Llovet, J.M., and Bruix, J. (2003). Systemic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442.
27. Llovet, J.M., Real, M.I., Montana, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., Rodés, J., and Bruix J.; Barcelona Liver Cancer Group. (2003). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma, a randomised controlled trial. Lancet 359, 1734-1739.
28. Lo, C.M., Ngan, H., Tso, W.K., Liu, C.L., Lam, C.M., Poon, R.T., Fan, S.T., and Wong, J. (2002). Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171.
29. Nagasue, N., Inokuchi, K., Kobayashi, M., Ogawa, Y., and Iwaki, A. (1976). Hepatic dearterialization for nonrespectable primary and secondary tumors of the liver. Cancer 38, 2593-2603.
30. Nakai, H., Thomas, C.E., Storm, T.A., Fuess, S., Powell, S., Wright, J.F., and Key, M.A. (2002). A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virusmediated liver transduction. J. Virol. 76, 11343-11349.
31. Nakanishi, K., Hiroi, S., Tominaga, S., Aida, S., Kasamatsu, H., Matsuyama, S., Matsuyama, T., and Kawai, T. (2005). Expression of hypoxia-inducible factor-1α protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin. Cancer Res. 11, 2583-2590.
32. O'Suilleabhain, C.B., Poon, R.T., Yong, J.L., Ooi, G.C., Tso, W.K., and Fan, S.T. (2003). Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br. J. Surg. 90, 325-331.
33. Pedersen, P.L. (2007). The cancer cell's "power plants" as promising therapeutic targets, an overview. J. Bioenerg. Biomembr. 39, 1-12.
34. Pelletier, G., Roche, A., Ink, O., Anciaux, M.L., Derhy, S., Rougier, P., Lenoir, C., Attali P., and Etienne, J.P. (1990). A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J. Hepatol. 11, 181-184.
35. Plengvantt, U., Chearanai, O., Sindhvananda, K., Damrongsak, D., Tuchinda, S., and Viranuvatti, V. (1972). Collateral arterial blood supply of the liver after hepatic artery ligation, angiographic study of twenty patients. Ann. Surg. 175, 105-110.
36. Ponnazhagan, S., Curiel, D.T., Shaw, D.R., Alvarez, R.D., and Siegal, G.P. (2001). Adeno-associated virus for cancer gene therapy. Cancer Res. 61, 6313-6321.
37. Poon, R.T., Lau, C., Yu, W.C., Fan, S.T., and Wong, J. (2004). High serum levels of vascular endothelial growth factor predict poor response to transcatheter arterial chemoembolization in hepatocellular carcinoma, a prospective study. Oncol. Rep. 11, 1077-1084.
38. Pugh, C.W., and Ratcliffe, P.J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med. 9, 677-684.
39. Rankin, E.B., Biju, M.P., Liu, Q., Unger, T.L., Rha, J., Johnson, R.S., Simon, M.C., Keith, B., and Haase, V.H. (2007). Hypoxiainducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068-1077.
40. Rankin, E.B., Rha, J., Unger, T.L., Wu, C.H, Shutt, H.P., Johnson, R.S., Simon, M.C., Keith, B., and Haase, V.H. (2008). Hypoxiainducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354-5358.
41. Ratcliffe, P.J. (2007). HIF-1 and HIF-2: Working alone or together in hypoxia? J. Clin. Invest. 17, 862-865.
42. + cells. Hum. Gene Ther. 9, 2727-2734.
43. Semenza, G.L. (2007). Life with oxygen. Science 318, 62-64.
44. Shin, D.H., Kim, J.H., Jung, Y.J., Kim, K.E., Jeong, J.M., Chun, Y.S., and Park, J.W. (2007). Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett. 255, 107-116.
45. Song, B.C., Chung, Y.H., Kim, J.A., Lee, H.C., Yoon, H.K., Sung, K.B., Yang, S.H., Yoo, K., Lee, Y.S., and Suh, D.J. (2001). Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Cancer 91, 2386-2393.
46. Song, X., Liu, X., Chi, W., Liu, Y., Wei, L., Wang, X., and Yu, J. (2006). Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemother. Pharmacol. 58, 776-784.
47. Sun, X., Kanwar, J.R., Leung, E., Lehnert, K., Wang, D., and Krissansen, G.W. (2001). Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8, 638-645.
48. Sure, U., Battenberg, E., Dempfle, A., Tirakotai, W., Bien, S., and Bertalanffy, H. (2004). Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral ateriovenous malformations. Neurosurgery 55, 663-670.
49. Tse, L., Sun, X., Jiang, H., Dong, X., Fung, P.W.C., Farzaneh, F., and Xu, R. (2008). Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J. Gene Med. 10, 508-517.
50. Unruh, A., Ressel, A., Mohamed, H.G., Johnson, R.S., Nadrowitz, R., Richter, E., Katschinski, D.M., and Wenger, R.H.(2003). The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 22, 3213-3220.
51. Wei, H., Wang, C., and Chen, L. (2006). Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1α. Pancreas 32, 159-163.
52. 2-regulated gene expression. FASEB J. 16, 1151-1162.
53. Williams, K.J., Telfer, B.A., Xenaki, D., Sheridan, M.R., Desbaillets, I., Peters, H.J., Honess, D., Harris, A.L., Dachs, G.U., van der Kogel, A., and Stratford, I.J. (2005). Enhanced response to radiotherapy in tumors deficient in the function of hypoxiainducible factor-1. Radiother. Oncol. 75, 89-98.
54. Xu, R., Sun, X., Chan, D., Tse, LY, Xu, S, Xiao, W., Kung, H.F., Krissansen, G.W., and Fan, S.T. (2003). Long-term expression of angiostatin suppresses liver metastatic cancer in mice. Hepatology 37, 1451-1460.
55. Yang, Z.F., Poon, R.T., To, J., Ho, D.W., and Fan, S.T. (2004). The potential role of hypoxia inducible factor 1a in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res. 64, 5496-5503.
56. Yasuda, S., Arii, S., Mori, A., Isobe, N., Yang, W., Oe, H., Fujimoto, A., Yonenaga, Y., Sakashita, H., and Imamura, M. (2004). Hexokinase II and VEGF expression in liver tumors, correlation with hypoxia-inducible factor 1a and its significance. J. Hepatol. 40, 117-123.